Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 392, Issue 1, pp 45–53 | Cite as

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice

  • Aly M. AbdelrahmanEmail author
  • Yousuf Al Suleimani
  • Asem Shalaby
  • Mohammed Ashique
  • Priyadarsini Manoj
  • Abderrahim Nemmar
  • Badreldin H. Ali
Original Article


Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor that is currently available for the management of type 2 diabetes mellitus. The present study investigated the effect of canagliflozin on cisplatin (CP)-induced nephrotoxicity in mice. The animals were divided into four groups (n = 6). The first and second groups received normal saline (control) and intraperitoneal (i.p.) cisplatin (20 mg/kg) on day 7, respectively. The third and fourth groups were given a single intraperitoneal (i.p.) injection of CP (20 mg/kg) on day 7 and canagliflozin (10 mg/kg/day) and (30 mg/kg/day), for 10 days, respectively. At day 11, animals were anesthetized and blood collected and kidneys were removed. CP significantly increased the plasma urea, creatinine, cystatin C, and clusterin concentrations and neutrophil gelatinase-associated lipocalin (NGAL) activity. In addition, CP increased urinary albumin/creatinine ratio, N-acetyl-β-D-glucosaminidase (NAG) activity, and liver-type fatty acid-binding protein (L-FABP) concentrations and reduced creatinine clearance. CP also significantly increased the plasma concentration of inflammatory cytokines [plasma tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1beta (IL-1β)] and significantly reduced antioxidant indices [catalase, glutathione reductase (GR), and superoxide dismutase (SOD)]. Histopathologically, CP caused a remarkable renal damage compared with control. Canagliflozin significantly ameliorated CP-induced biochemical and histopathological changes. The protective effect of canagliflozin is most likely due to anti-inflammatory and antioxidant effects. Our results show that administration of canagliflozin reversed the biochemical and histopathological indices of CP-induced nephrotoxicity in mice.


Cisplatin Canagliflozin Sodium glucose co-transporter 2 inhibitors Nephrotoxicity 



We thank Ms. Halima Al Isaai for the help with the preparation of histopathology slides.

Author contribution

A.N. and B.A. conceived and designed research.

A.A., Y.S., and A.N.; B.A. participated in the interpretation of the results, writing and review of the manuscript.

A.S. performed the histological analysis.

M.A. conducted the experiments and analysis of data.

P.M. conducted the experiments and analysis of data.

All authors read and approved the manuscript.

Funding information

This study was supported by a grant from Sultan Qaboos University (IG/MED//PHAR/17/01).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. Abdelrahman AM, Al Salam S, AlMahruqi AS, Al husseni IS, Mansour MA, Ali BH (2010) N-acetylcysteine improves renal hemodynamics in rats with cisplatin-induced nephrotoxicity. J Appl Toxicol 30:15–21CrossRefGoogle Scholar
  2. Abdel-Wahab AF, Bamagous GA, Al-Harizy RM, ElSawy NA, Shahzad N, Ibrahim IA, Ghamdi SSA (2018) Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. Biomed Pharmacother 103:59–66CrossRefGoogle Scholar
  3. Al Suleimani YM, Abdelrahman AM, AlMahruqi AS, Alhseini IS, Tageldin MH, Mansour ME, Ali BH (2010) Interaction of nimesulide, a cyclooxygenase-2 inhibitor, with cisplatin in normotensive and spontaneously hypertensive rats. Food Chem Toxicol 48:139–144CrossRefGoogle Scholar
  4. Ali BH, Al Moundhri MS (2006) Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 44:1173–1183CrossRefGoogle Scholar
  5. Ali BH, Abdelrahman AM, Al-Salam S, Sudhadevi M, AlMahruqi AS, Al-Husseni IS, Beegam S, Dhanasekaran S, Nemmar A, Al-Moundhri M (2011) The effect of sildenafil on cisplatin nephrotoxicity in rats. Basic Clin Pharmacol Toxicol 109:300–308CrossRefGoogle Scholar
  6. Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460–464CrossRefGoogle Scholar
  7. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB (2014) Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 8:262–275CrossRefGoogle Scholar
  8. Chang Y-K, Choi H, Jeong JY, Na K-R, Lee KW, Lim BJ, Choi DE (2016) Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS ONE 11(7):e0158810. CrossRefGoogle Scholar
  9. Chatterjee PK, Yeboah MM, Solanki MH, Kumar G, Xue X, Pavlov VA, Al-Abed Y, Metz CN (2017) Activation of the cholinergic anti-inflammatory pathway by GTS-21 attenuates cisplatin-induced acute kidney injury in mice. PLoS ONE 12(11):e0188797. CrossRefGoogle Scholar
  10. Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI (2017) A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 22:609–619CrossRefGoogle Scholar
  11. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int.
  12. Huang YC, Tsai MS, Hsieh PC, Shih JH, Wang TS, Wang YC, Lin TH, Wang SH (2017) Galangin ameliorates cisplatin-induced nephrotoxicity by attenuating oxidative stress, inflammation and cell death in mice through inhibition of ERK and NF-kappaB signaling. Toxicol Appl Pharmacol 329:128–139CrossRefGoogle Scholar
  13. Ji W, Zhao M, Wang M, Yan W, Liu Y, Ren S, Lu J, Wang B, Chen L (2017) Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS One 12(6):e0179960. eCollection 2017CrossRefGoogle Scholar
  14. Kim J, Long KE, Tang K, Padanilam BJ (2012) Poly (ADP- ribose) polymerase 1 activation is required for cisplatin nephrotoxicity. Kidney Int 82:193–203CrossRefGoogle Scholar
  15. Kimoto Y, Nishinohara M, Sugiyama A, Haruna A, Takeuchi T (2013) Protective effect of lactoferrin on cisplatin-induced nephrotoxicity in rats. J Vet Med Sci 75:159–164CrossRefGoogle Scholar
  16. Lovshin JA, Gilbert RE (2015) Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective. Curr Hypertens Rep 17(6):551. CrossRefGoogle Scholar
  17. Ma Q, Steiger S, Anders H-J (2017) Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease. Physiol Rep 5(7):e13228. CrossRefGoogle Scholar
  18. Maliha G, Townsend RR (2015) SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens 9:48–53CrossRefGoogle Scholar
  19. Manohar S, Leung N (2018) Cisplatin nephrotoxicity: a review of the literature. J Nephrol 31:15–25CrossRefGoogle Scholar
  20. Meng H, Fu G, Shen J, Shen K, Xu Z, Wang Y, Jin B, Pan H (2017) Ameliorative effect of daidzein on cisplatin-induced nephrotoxicity in mice via modulation of inflammation, oxidative stress, and cell death. Oxid Med Cell Longev 2017:3140680. CrossRefGoogle Scholar
  21. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins 2:2490–2518. CrossRefGoogle Scholar
  22. Naznin F, Sakoda H, Okada T, Tsubouchi H, Waise TM, Arakawa K, Nakazato M (2017) Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur J Pharmacol 794:37–44CrossRefGoogle Scholar
  23. Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S (2015) Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res 47:686–692CrossRefGoogle Scholar
  24. Oliva RV, Bakris GL (2014) Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 8:330–339CrossRefGoogle Scholar
  25. Sharp CN, Siskind LJ (2017) Developing better mouse models to study cisplatin-induced kidney injury. Am J Physiol Renal Physiol 313:F835–F841CrossRefGoogle Scholar
  26. Sheikh-Hamad D, Timmins K, Jalali Z (1997) Cisplatin-induced renal toxicity: possible reversal by N-acetylcysteine. J Am Soc Nephrol 8:1640–1645Google Scholar
  27. Tahara A, Takasu T (2018a) Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice. Naunyn Schmiedeberg’s Arch Pharmacol 391:395–406CrossRefGoogle Scholar
  28. Tahara A, Takasu T (2018b) Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice. Eur J Pharmacol 830:68–75CrossRefGoogle Scholar
  29. Tang L, Wu Y, Tian M, Sjöström CD, Johansson U, Peng XR, Smith DM, Huang Y (2017) Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab 313:E563–E576CrossRefGoogle Scholar
  30. Tosaki T, Kamiya H, Himeno T, Kato Y, Kondo M, Toyota K, Nishida T, Shiroma M, Tsubonaka K, Asai H, Moribe M, Nakaya Y, Nakamura J (2017) Sodium-glucose co-transporter 2 inhibitors reduce the abdominal visceral fat area and may influence the renal function in patients with type 2 diabetes. Intern Med 56:597–604CrossRefGoogle Scholar
  31. Yang H, Li W, Wang L, Li W, Sun H, He X, Zhang J (2017) The protective effects of sika deer antler protein on cisplatin-induced nephrotoxicity. Cell Physiol Biochem 43:395–404CrossRefGoogle Scholar
  32. Zhang Y, Thai K, Kepecs DM, Gilbert RE (2016) Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS One 11(1):e0144640. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health SciencesSultan Qaboos UniversityMuscatOman
  2. 2.Department of Pathology, College of Medicine and Health SciencesSultan Qaboos UniversityMuscatOman
  3. 3.Department of Physiology, College of Medicine and Health SciencesUnited Arab Emirates UniversityAl AinUAE

Personalised recommendations